AVERROES PHARMA
Open bankruptcyA bankruptcy procedure is open for AVERROES PHARMA according to publications in the Belgian State Gazette; curator: Dirk DE MAESENEER.
Summary
The 2021 annual accounts show negative equity (-€35,369) and a net result of -€36,368.
Are you a creditor?
Open bankruptcy
Source: Belgian Official Gazette
If this company owes you money, you are not paid automatically: you file your claim yourself, within the deadline the judgment sets.
The procedure
- Court
- Enterprise Court of Brussels
- Declared bankrupt
- 4 February 2025
- Supervising judge
- Stijn Crombe
- Official Gazette
- 10-02-2025 (pdf) ↗search the document for 2025/105523
Deadlines
- Provisional date payments stopped
- 4 February 2025A later judgment can change the date.art. XX.105 CEL
- Appeal or third-party opposition until
- passed on 25 February 2025Fifteen days after the publication in the Official Gazette.art. XX.108 CEL
- File the claim in RegSol until
- passed on 6 March 2025art. XX.104 and XX.155 CEL
- First verification report
- passed on 12 March 2025Goods that belong to you, such as those delivered under retention of title, are reclaimed before this day.art. XX.104 and XX.194 CEL
- Late claim until
- passed on 4 February 2026Late, you share only in what has not been paid out yet, and the costs are yours.art. XX.165 CEL
Curator
- Dirk De MaeseneerPegasuslaan 5, 1831 Diegemdirk.de.maeseneer@lovanius.be
What to do now
- Do not deliver on credit any more without an agreement with the curator.
- Gather your documents: invoices, purchase orders, contract, delivery notes and reminders.
- File your proof of claim in RegSol (regsol.be), yourself with eID or itsme, or through your lawyer. State principal, interest and costs separately, and any preferential right you hold.
- Delivered under retention of title? Reclaim your goods before the first report on the verification of claims.
- Ask your accountant about the VAT on the unpaid invoices: in a bankruptcy it can be recovered under conditions.
- Follow the file in RegSol: the verification report (admitted or disputed) and the curator's reports appear there.
The deadlines above come from the publication of the judgment. Check them in RegSol before you file anything; a passed deadline no longer applies.
File a claim in RegSol ↗
Watch
Follow this bankruptcy: you are alerted when it is closed or reversed.
General information, not legal advice. If in doubt, the curator, your lawyer or your accountant can help.Creditor guide for this company
Embed in an article
Writing about this bankruptcy? Put the card of AVERROES PHARMA in your article: name, enterprise number, its status in the KBO and the latest annual accounts, with a link to this dossier.
Preview
The preview appears here.
- Stays current: the status follows the register, the figures are those of the latest filed accounts. No Checked score or verdict.
- Light on your page: one small script and one data request, also answered from a cache; no cookies, no tracking.
- Where scripts do not run (a newsletter, a feed reader) a plain link remains.
Signals
Three signals. The signal on the left, the evidence on the right.
+raises risk○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2021 was due by 31-07-2022 and was filed on 07-07-2022, 24 days ahead of the deadline.
NBB · 2 filingsDeviation from the deadline
2025
not confirmed
2024
not filed
2023
not filed
2022
not filed
2021
24 d early
2020
72 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 2 accounts on average 24 days after the deadline; the sector median for financial year 2024 is on the deadline day, and 46% of the sector filed late.
Checked, nothing found (1)
History
Go further with this company
Who ran this company, and where was it based, on a date before the end?Company as of a date Is the registered address a letterbox address or a business centre?Addresses Are there other customers at risk in your own list?List enrichment How is the Retail sale of pharmaceutical products sector doing?Sector figures
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2021, micro schema
Equity
-€35,369
2020 · €999
Total assets
€81,255▲ 875%
2020 · €8,331
Net result
-€36,368▼ 91.4%
2020 · -€19,001
Working capital
-€47,282
2020 · €249
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 47, Retail trade, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20202021
Operating result-€18,992--€36,113▼ 90.2%
Net result-€19,001below the sector's middle half--€36,368below the sector's middle half▼ 91.4%
Equity€999below the sector's middle half--€35,369below the sector's middle half
Total assets€8,331below the sector's middle half-€81,255within the sector's middle half▲ 875%
Debt€7,332-€116,624▲ 1,491%
Working capital€249within the sector's middle half--€47,282below the sector's middle half
Solvency12.0%within the sector's middle half--43.5%below the sector's middle half▼ 55.5pp
Current ratio1.04within the sector's middle half-0.59below the sector's middle half▼ 0.44
Return on assets (ROA)-228.1%below the sector's middle half--44.8%below the sector's middle half▲ 183.3pp
Staff (FTE)1
above
within
below
the middle half (P25 to P75) of NACE 47, Retail trade, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €36,113 in 2021 against €18,992 in 2020; the loss grows.
Balance-sheet composition
2021 in colour, 2020 as the grey bar beneath
Assets €81,255
Fixed assets
€12,041 ▲ 625%
Current assets
€69,214 ▲ 938%
Key figures and ratios
EBITDA
-€35,734
Cash flow
-€35,990
Quick ratio
0.31▼
2020 · 1.04
Debt to equity
-3.30
Interest coverage
-139.73
Debt ≤ 1 year
€116,496▲
2020 · €6,422
Staff costs
€11,927
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2020 | 2021 | Change |
|---|---|---|---|
| Remuneration, social security and pensions62 | - | €11,927 | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | - | €379 | - |
| Gross operating margin9900 | -€18,992 | -€23,806 | ▼ 25.4% |
| Operating profit (loss)9901 | -€18,992 | -€36,113 | ▼ 90.2% |
| Financial charges65/66B | - | €256 | - |
| Recurring financial charges65 | €9 | €256 | ▲ 2,689% |
| Profit (loss) for the period before taxes9903 | -€19,001 | -€36,368 | ▼ 91.4% |
| Profit (loss) for the period9904 | -€19,001 | -€36,368 | ▼ 91.4% |
| Profit (loss) for the period to be appropriated9905 | -€19,001 | -€36,368 | ▼ 91.4% |
| Line | 2020 | 2021 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €8,331 | €81,255 | ▲ 875% |
| Fixed assets21/28 | €1,660 | €12,041 | ▲ 625% |
| Tangible fixed assets22/27 | - | €10,381 | - |
| Plant, machinery and equipment23 | - | €3,306 | - |
| Furniture and vehicles24 | - | €7,075 | - |
| Financial fixed assets28 | €1,660 | €1,660 | = |
| Current assets29/58 | €6,671 | €69,214 | ▲ 938% |
| Stocks and contracts in progress3 | - | €33,503 | - |
| Stocks30/36 | - | €33,503 | - |
| Amounts receivable within one year40/41 | €4,208 | €14,675 | ▲ 249% |
| Trade receivables40 | - | €8,968 | - |
| Other amounts receivable41 | - | €5,708 | - |
| Cash at bank and in hand54/58 | €2,463 | €20,865 | ▲ 747% |
| Deferred charges and accrued income490/1 | - | €170 | - |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €8,331 | €81,255 | ▲ 875% |
| Equity10/15 | €999 | -€35,369 | ▼ 3,640% |
| Contributions10/11 | - | €20,000 | - |
| Profit (loss) carried forward14 | -€19,001 | -€55,369 | ▼ 191% |
| Amounts payable17/49 | €7,332 | €116,624 | ▲ 1,491% |
| Amounts payable within one year42/48 | €6,422 | €116,496 | ▲ 1,714% |
| Trade debts44 | €4,364 | €72,607 | ▲ 1,564% |
| Suppliers440/4 | - | €72,607 | - |
| Taxes, remuneration and social security45 | - | €2,796 | - |
| Taxes450/3 | - | €784 | - |
| Remuneration and social security454/9 | - | €2,012 | - |
| Other amounts payable47/48 | - | €41,092 | - |
| Accrued charges and deferred income492/3 | - | €128 | - |
| Line | 2020 | 2021 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | -€19,001 | -€36,368 | ▼ 91.4% |
| + Depreciation and write-downs630 | - | €379 | - |
| Operating cash flow (approximation) | -€19,001 | -€35,990 | ▼ 89.4% |
| Investment in fixed assets (approximation) | - | -€10,760 | - |
| Change in cash | - | €18,402 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
10-02
Bankruptcy
Opening
Ondernemingsrechtbank Brussel · event 04-02-2025
2022
07-07
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
11-10
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema · 72 days late
SignalNBB filing
0 of 4 acts read
About the unread acts
We know of 4 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
4 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Sint-Jans-Molenbeek · 1 establishment unit since 2019
Ground area
252 m²
Building footprint
123 m²
Volume, LiDAR
1,895 m³
2 parcels, Brussels · tallest building 23.2 m, ±7 floors. Linked by address, not a title deed.
3
companies at this address
See who is registered here
1 establishment unit
AVERROES PHARMA
since 20192.316.022.676
2 parcels
Brussels
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21012A0078/00G006 | Brussels | 134 m² | 1 · 50 m² | 23.2 m · 7 fl. |
| 21572B0012/00S005 | Brussels | 118 m² | 1 · 73 m² | 14.9 m · 4 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Insolvency mandates
1 mandate| Role | Name | Tenure |
|---|---|---|
| Curator | Dirk DE MAESENEER PEGASUSLAAN 5, 1831 DIEGEM- |
04-02-2025 → present |
Recognitions · licences · registrations
Food safety, FASFC
1 siteSint-Joost-ten-Node2.316.022.676
Similar companies · same sector, comparable size
APOTHEEK VERSCHAEVE-BARTELEN
BE 0451.903.303
Beveren-Kruibeke-Zwijndrecht · Eq €1,000
LISANNE MOONS
BE 0737.837.230
Zonhoven · Eq €1,000
Farmaco
BE 0746.369.666
Ranst · Eq €1,000
APOTHEEK VERSE
BE 0893.942.595
Brussel · Eq €912
MDN Pharmaceutics
BE 1032.175.218
Brussel · Eq €873
Of 5,220 companies in sector 47730 we hold annual accounts for 3,862. 87 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded06-12-2019
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
Contact
E-mail
averroes.brussels@gmail.comSint-Joost-ten-Node
Phone
0032465888839Sint-Joost-ten-Node
E-invoicing
Not found in the Peppol register
No Peppol card under this enterprise or VAT number. That proves nothing: publishing a card is voluntary.
Register as of 28 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.